Form D · Biotechnology
NEUROONE MEDICAL TECHNOLOGIES Corp
Eden Prairie, MN · CIK 0001500198
Offering snapshot reported Aug 16, 2024 · SEC filing
- Reported sold
- $276K Offering amount: $276K
- Investors reported
- 20 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 2, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 16, 2024 | Initial | $276,043 | No comparison | 20 | SEC filing |
| Jan 27, 2021 | Initial | $12,500,000 | No comparison | 36 | SEC filing |
| Aug 10, 2020 | Initial | $135,000 | No comparison | 1 | SEC filing |
| May 14, 2020 | Initial | $2,469,800 | No comparison | 33 | SEC filing |
| Nov 7, 2019 | Initial | $255,000 | No comparison | 3 | SEC filing |
| Nov 7, 2019 | Initial | $1,253,000 | No comparison | 16 | SEC filing |
| Feb 27, 2019 | Amendment | $992,500 | $592,500vs Jan 4, 2019 | 17 | SEC filing |
| Feb 27, 2019 | Amendment | $1,538,000 | $1,000,000vs Jul 24, 2018 | 21 | SEC filing |
| Jan 4, 2019 | Initial | $400,000 | No comparison | 3 | SEC filing |
| Jul 24, 2018 | Initial | $538,000 | No comparison | 4 | SEC filing |
| May 23, 2018 | Amendment | $1,490,000 | $825,000vs Dec 21, 2017 | 20 | SEC filing |
| Dec 21, 2017 | Amendment | $665,000 | $515,000vs Oct 18, 2017 | 12 | SEC filing |
| Oct 18, 2017 | Initial | $150,000 | No comparison | 3 | SEC filing |
| Aug 29, 2017 | Initial | $253,000 | No comparison | 2 | SEC filing |
| Aug 2, 2017 | Initial | $0 | No comparison | 19 | SEC filing |
Offering details
- Securities
- Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-521739
The offering amount excludes proceeds of up to $2,627,923 from warrant exercises, and a warrant to purchase 100,000 shares issued in connection with a loan and security agreement and proceeds of up to $66,000 from the exercise of such warrant.
Source: Form D, filed Aug 16, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Edward Andrle | Director |
| Thomas Bachinski | Executive |
| Paul Buckman | Director |
| Mark Christianson | Executive |
| Suraj Kalia | Director |
| Jeffrey S. Mathiesen | Director |
| Ronald Mc Clurg | Executive |
| Steve Mertens | Executive |
| David A. Rosa | Director, Executive |
| Amer Samad | Director |
| Christopher Volker | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
7599 Anagram Dr
Eden Prairie, MN, 55344
Eden Prairie, MN, 55344